In December 2013 we successfully acquired HER-Vaxx  from Biolife Science

Imugene Investor Center

Current and prospective shareholders can access a range of information about Imugene in this section of the website and keep up-to-date on Company performance and activities.

You will be able to access financial information and the Company's most recent announcement.

Download the Imugene Fact Sheet

Shareholders, media and prospective shareholders can contact us by email at: info@imugene.com

Share Price | Contact Us

 

Subscribe to our mailing list

* indicates required
Are you a shareholder? *
Email Format
 
 
 

© Imugene 2017. All rights reserved. ABN 99 009 179 551